Inogen stock analysis
Want to see INGN full AI Analyst Report?
Inogen (INGN) Stock Price & Analysis
INGN Stock Chart & Stats
- Day’s Range
- $5.69 - $6.01
- 52-Week Range
- $5.05 - $7.67
- Previous Close
- $6.00
- Volume
- N/A
- Average Volume (3M)
- 331.78K
- Market Cap
- $156.01M
- Enterprise Value
- $56.67M
- Total Cash (Recent Filing)
- $96.84M
- Total Debt (Recent Filing)
- $14.93M
- Price to Earnings (P/E)
- ―
- Beta
- 0.83
- Next Earnings
- Feb 25, 2027 (Est.)
- EPS Estimate
- -0.2
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Strong Liquidity And Low Leverage
A debt-free balance sheet and substantial liquidity provide financial flexibility while Inogen works through operating losses. This supports continued investment in products and commercial capabilities, reduces refinancing pressure, and gives management more time to execute its restructuring and growth plans.
Core Product Volume And U.S. Demand Growth
Higher portable oxygen concentrator volumes and renewed U.S. sales growth indicate ongoing demand for Inogen’s core respiratory products. Distributor-driven adoption and contributions from new products can strengthen the installed base, improve scale, and provide a foundation for more durable revenue growth.
Strategic Streamlining And Cost Savings
Exiting the rental business and reducing the operating-cost base should simplify execution and concentrate resources on higher-priority opportunities. If implemented as planned, the savings can improve operating leverage, reduce the break-even revenue level, and support a clearer path toward sustainable profitability.
Bears Say
Persistent Unprofitability And Revenue Contraction
The core business remains loss-making while revenue has softened, limiting operating leverage and reducing the resources available for internally funded growth. Although profitability improved from earlier periods, continued negative earnings show that the current commercial and cost structure has not yet produced consistently sustainable returns.
Negative Cash Generation
Persistent cash burn means Inogen is not currently funding its operations and investments internally. Even with low debt and strong liquidity today, sustained negative cash flow can gradually erode financial flexibility, constrain capital allocation, and increase dependence on successful cost reductions and business improvement.
International Weakness And Margin Pressure
Weak international demand, including softer European customer spending and inventory management, is creating a meaningful revenue headwind. Continued softness can dilute scale benefits and pressure margins, making the company more reliant on U.S. growth, new products, and cost actions to offset regional weakness.
INGN FAQ
What was Inogen’s price range in the past 12 months?
What is Inogen’s market cap?
When is Inogen’s upcoming earnings report date?
How were Inogen’s earnings last quarter?
Is Inogen overvalued?
Does Inogen pay dividends?
What is Inogen’s EPS estimate?
How many shares outstanding does Inogen have?
What happened to Inogen’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Inogen?
What is the TipRanks Smart Score and how is it calculated?
Inogen Stock Smart Score
Company Description
Inogen
Inogen, Inc. operates as a medical technology enterprise dedicated to designing, fabricating, and distributing oxygen concentration equipment. These cutting-edge devices are engineered to provide continuous oxygen support for patients managing persistent respiratory conditions. The company's diverse product range features the popular portable Inogen One, which efficiently draws oxygen from the surrounding atmosphere to offer an independent supply, alongside stationary Inogen At Home concentrators, Tidal Assist Ventilators, and various associated accessories. Inogen serves a broad clientele, including individual patients, medical professionals, and insurance providers, both domestically in the United States and globally. Furthermore, the company facilitates direct equipment rentals to patients. Founded in 2001, Inogen, Inc. is headquartered in Goleta, California.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin R. Smith
- Employees
- 753
- Website
- www.inogen.com
- Address
- 500 Cummings Center, Beverly, MA, 01915, US
Inogen (INGN) Earnings & Revenues
INGN Company Deck
INGN Earnings Call
Earnings Call SentimentNeutral
The call presented a mixed outlook. Positive developments included a return to U.S. sales growth, higher portable oxygen concentrator volumes, completion of the rental divestiture, substantial planned cost savings, strong liquidity, and investments in new products and adjacent respiratory markets. These were offset by declining total and international revenue, lower gross margin, reduced adjusted profitability, a larger GAAP loss, negative operating cash flow, and guidance for a full-year adjusted net loss. Management expressed confidence in the company's assets and strategy but acknowledged that financial results need to improve.
View all INGN earnings summariesINGN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 5 | 14 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 0 | 0 | 12 |













